Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2

Cancer Science

Volumn 106, Issue 3, 2015, Pages 279-286

  Wongthai, Printip ^a   Hagiwara, Kohei ^a   Miyoshi, Yurika ^b   Wiriyasermkul, Pattama ^a   Wei, Ling ^a   Ohgaki, Ryuichi ^a   Kato, Itsuro ^c   Hamase, Kenji ^b   Nagamori, Shushi ^a   Kanai, Yoshikatsu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Amino acid transporter; BNCT; BPA; Cancer cell lines; Drug delivery

Indexed keywords

4 BORONOPHENYLALANINE; AMINO ACID TRANSPORTER; AROMATIC AMINO ACID TRANSPORTER ATB; AROMATIC AMINO ACID TRANSPORTER LAT1; AROMATIC AMINO ACID TRANSPORTER LAT2; UNCLASSIFIED DRUG; 4-BORONOPHENYLALANINE; BORON; BORON DERIVATIVE; CD98 ANTIGEN; NEUROTRANSMITTER TRANSPORTER; PHENYLALANINE; SLC6A14 PROTEIN, RAT; SLC7A7 PROTEIN, MOUSE; SLC7A8 PROTEIN, MOUSE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG UPTAKE; HELA CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MCF 7 CELL LINE; NEUTRON CAPTURE THERAPY; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSPORT ASSAY; TRANSPORT KINETICS; XENOPUS; ANALOGS AND DERIVATIVES; ANIMAL; HUMAN; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM Y+; AMINO ACID TRANSPORT SYSTEMS; ANIMALS; ANTIGENS, CD98 LIGHT CHAINS; BIOLOGICAL TRANSPORT; BORON; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; CELL LINE, TUMOR; HELA CELLS; HUMANS; MCF-7 CELLS; NEUROTRANSMITTER TRANSPORT PROTEINS; OOCYTES; PHENYLALANINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOPUS;

EID: 84925744386     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12602     Document Type: Article

References (36)

1. Barth RF, Vicente MGH, Harling OK et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 2012; 7: 146.
2. Kato I, Ono K, Sakurai Y et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 2004; 61: 1069-73.
3. Yoshida F, Matsumura A, Yamamoto T, Kumada H, Nakai K. Enhancement of sodium borocaptate (BSH) uptake by tumor cells induced by glutathione depletion and its radiobiological effect. Cancer Lett 2004; 215: 61-7.
4. Yokoyama K, Miyatake S, Kajimoto Y et al. Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT. J Neurooncol 2006; 78: 227-32.
5. Wittig A, Sauerwein WA, Coderre JA. Mechanisms of transporters of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res 2000; 153: 173-80.
6. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009; 121: 29-40.
7. Detta A, Cruickshank GS. L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res 2009; 69: 2126-32.
8. 18F-fluoro-phenylalanin uptake in human glioblastome cells. Nucl Med Biol 2013; 40: 625-9.
9. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime. Semin Cancer Biol 2005; 15: 254-66.
10. Kanai Y, Endou H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2001; 2: 229-354.
11. Nakada N, Mikami T, Hana K et al. Unique and selective expression of L-amino acid transporter 1 in human tissue as well as being an aspect of oncofetal protein. Histol Histopathol 2014; 29: 217-27.
12. Kanai Y, Segawa H. Miyamoto Ki, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23629-32.
13. Uchino H, Kanai Y, Kim DK et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 2002; 61: 729-37.
14. Kaira K, Oriuchi N, Otani Y et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res 2007; 13: 6369-78.
15. Wiriyasermkul P, Nagamori S, Tominaga H et al. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med 2012; 53: 1253-61.
16. Laurent T, Murase D, Tsukioka S, Matsuura T, Nagamori S, Oda H. A novel human hepatoma cell line, FLC-4, exhibits highly enhanced liver differentiation functions through the three-dimensional cell shape. J Cell Physiol 2012; 227: 2898-906.
17. Miyoshi Y, Oyama T, Itoh Y, Hamase K. Enantioselective two-dimensional high-performance liquid chromatographic determination of amino acids; analysis and physiological significance of D-amino acids in mammals. Chromatography 2014; 35: 49-57.
18. Khunweeraphong N, Nagamori S, Wiriyasermkul P et al. Establishment of stable cell lines with high expression of heterodimers of human 4f2hc and human amino acid transporter LAT1 or LAT2 and delineation of their differential interaction with α-alkyl moieties. J Pharmacol Sci 2012; 119: 368-80.
19. Sahoo S, Aurich MK, Jonsson JJ, Thiele I. Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease. Front Physiol 2014; 5: 91.
20. 18F]fluoroethyl)methyl-amino)ethyltyrosine. Mol Imaging Biol 2014; 16: 412-20.
21. --dependent neutral and cationic amino acid transporter B0+. J Biol Chem 1999; 274: 23740-5.
22. 0, +) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J Biol Chem 2011; 286: 31830-8.
23. 0, +) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J 2008; 414: 343-55.
24. +-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem 1999; 274: 19745-51.
25. 123I]IMT) transport in human GOS3 glioma cells. Nucl Med Biol 2001; 28: 293-7.
26. Coderre JA, Elowitz EH, Chadha M et al. Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results. J Neurooncol 1997; 33: 141-52.
27. Joel DD, Coderre JA, Micca PL, Nawrocky MM. Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy. J Neurooncol 1999; 41: 213-21.
28. Smith DR, Chandra S, Barth RF, Yang W, Joel DD, Coderre JA. Quantitative imaging and microlocalization of boron-10 in brain tumors and infiltrating tumor cells by SIMS ion microscopy: relevance to neutron capture therapy. Cancer Res 2001; 61: 8179-87.
29. Wyss MT, Hofer S, Hefti M et al. Spatial Heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med 2007; 48: 1047-52.
30. Henriksson R, Capala J, Michanek A et al. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 2008; 88: 183-91.
31. Barth RF, Coderre JA, Vicente MG, Blue ET. Boron Neutron Capture Therapy of Cancer: current Status and Future Prospects. Clin Cancer Res 2005; 11: 3987-4002.
32. Uhlen M, Oksvold P, Fagerberg L et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248-50.
33. Haining Z, Kawai N, Miyake K et al. Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas. BMC Clin Pathol 2012; 12: 4. doi:10.1186/1472-6890-12-4.
34. Nawashiro H, Otani N, Shinomiya N et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006; 119: 484-92.
35. 0, + (SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta 2005; 1741: 215-23.
36. Di Pierro D, Lazzarino G, Pastore FS et al. Determination of boronophenylalanine in biological samples using precolumn o-phthalaldehyde derivatization and reversed-phase high-performance liquid chromatography. Anal Biochem 2000; 284: 301-6.